Mutation Testing for Directing Upfront Targeted Therapy and Post-Progression Combination Therapy Strategies in Lung Adenocarcinoma

Expert Review of Molecular Diagnostics - United Kingdom
doi 10.1080/14737159.2016.1181545
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Lung Adenocarcinoma: Guiding EGFR-targeted Therapy and Beyond

Modern Pathology
Forensic MedicinePathology
2008English

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma

Scientific Reports
Multidisciplinary
2019English

Dasatinib-Induced Pulmonary Arterial Hypertension Treated With Upfront Combination Therapy

Case Reports in Cardiology
Cardiovascular MedicineCardiology
2018English

P1.13-20 MET Protein Expression and Activation During Targeted Therapy in EGFR Mutated Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-L1 Assessment for Targeted Therapy Testing in Cancer

Applied Immunohistochemistry and Molecular Morphology
Forensic MedicinePathologyMedical Laboratory TechnologyHistology
2017English

Escalation Strategies for Combination Therapy Phase I Trials

Pharmaceutical Statistics
StatisticsProbabilityPharmacology
2012English

Evidence for Self-Renewing Lung Cancer Stem Cells and Their Implications in Tumor Initiation, Progression, and Targeted Therapy

Cancer and Metastasis Reviews
Cancer ResearchOncology
2010English

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

MA27.10 EGFR-Targeted Therapy Alters the Tumor Microenvironment in EGFR-Driven Lung Tumors: Rationale for Combination Therapies

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy